These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11146982)

  • 1. The impact of 1990 Medicaid drug rebates policy on access to prescriptions.
    Okunade AA
    J Health Soc Policy; 2001; 12(3):33-51. PubMed ID: 11146982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remember the MaineRx.
    Kemp R
    Appl Health Econ Health Policy; 2014 Feb; 12(1):1-5. PubMed ID: 24420789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Price indexes for pharmaceuticals used by the elderly.
    Thomas J; Schondelmeyer S
    Health Care Financ Rev; 1992; 14(1):91-105. PubMed ID: 10124442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription-drug prices.
    Frank RG
    N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
    [No Abstract]   [Full Text] [Related]  

  • 5. Changing prescription drug sector: new expenditure methodologies.
    Genuardi JS; Stiller JM; Trapnell GR
    Health Care Financ Rev; 1996; 17(3):191-204. PubMed ID: 10158730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.
    Rome BN; Patel AN; Kesselheim AS
    Health Aff (Millwood); 2023 Jun; 42(6):770-778. PubMed ID: 37276474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
    Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
    [No Abstract]   [Full Text] [Related]  

  • 9. Medicaid prescription drug utilization and expenditures following Part D.
    Farley JF; Dusetzina SB
    J Health Care Poor Underserved; 2010 May; 21(2):715-28. PubMed ID: 20453368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in Medicaid Rebates Paid by Pharmaceutical Manufacturers for Outpatient Infused, Injected, Implanted, Inhaled, or Instilled Drugs: The 5i Loophole.
    Dickson S; Gabriel N; Gellad W; Hernandez I
    J Health Polit Policy Law; 2022 Dec; 47(6):835-851. PubMed ID: 35867551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State and federal government mandates are changing the face of pharmacy management.
    Giaquinta D
    Manag Care Interface; 2001 May; 14(5):50-2. PubMed ID: 11385948
    [No Abstract]   [Full Text] [Related]  

  • 12. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 13. Perverse incentives in the Medicare prescription drug benefit.
    McAdams D; Schwarz M
    Inquiry; 2007; 44(2):157-66. PubMed ID: 17850042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costs.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2004 Feb; 350(6):608-13. PubMed ID: 14762190
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of accessibility to drugs for patients in the years 1996-2001].
    Drozd M
    Wiad Lek; 2002; 55 Suppl 1(Pt 2):651-4. PubMed ID: 17474578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives. Fences loom for free-ranging drug prices.
    Kent C
    Faulkner Grays Med Health; 1991 Oct; 45(39):suppl 4 p. PubMed ID: 10113759
    [No Abstract]   [Full Text] [Related]  

  • 17. Prescription drugs are the biggest bargain in health care, and all Americans should have access to them.
    Holmer AF
    Md Med; 2003; 4(2):48-9. PubMed ID: 12847830
    [No Abstract]   [Full Text] [Related]  

  • 18. The reimbursement factor in pharmaceutical regulation: rebates, cost-effectiveness, and practice guidelines.
    Shulman SR
    Pharmacoeconomics; 1992; 1(Suppl 1):21-7. PubMed ID: 10146927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMCP Guide to Pharmaceutical Payment Methods.
    AMCP Task Force on Drug Payment Methodologies
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl C):S1-39. PubMed ID: 17970611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How do state Medicaid programs determine what substance use disorder treatment medications need prior authorization? An overview for clinicians.
    Bachhuber MA
    Addict Sci Clin Pract; 2020 Jun; 15(1):20. PubMed ID: 32600402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.